Serum Receptor Activator of Nuclear Factor-? B Ligand, Osteoprotegrin, and Intact Parathyroid Hormone in Hemodialysis and Renal Transplant Patients
Mahmoudi Meimand, S
MetadataShow full item record
Serum receptor activator of nuclear factor-? B ligand and osteoprotegrin are mediated to vascular calcification in the general population. Our knowledge is very sparse in hemodialysis and renal transplant patients. Receptor activator of nuclear factor-? B ligand, osteoprotegrin, intact parathyroid hormone, calcium, and phosphorus were measured in blood samples of 45 hemodialysis and 45 age-matched renal transplant patients. Osteoprotegrin (P=0.001) and intact parathyroid hormone (P=0.001) levels in the hemodialysis patients were higher than the renal transplant recipients. Osteoprotegrin had positive correlation with duration of dialysis and age in the hemodialysis (r=0.88, P=0.001 and r=0.34, P=0.02, respectively) and renal transplant patients (r=0.92, P=0.001 and r=0.46, P=0.001, respectively). Hemodialysis patients have higher osteoprotegrin levels than the renal transplant recipients. It may act as a protective factor for renal osteodystrophy or only as a secondary phenomenon of advanced renal failure. © 2012 International Society for Apheresis.
Showing items related by title, author, creator and subject.
The effect of cholecalciferol injection on serum 25 hydroxy vitamin D and parathyroid hormone in obese and none obese reproductive age women Ostadrahimi, A; Mahboob, S; Abbasalizad Farhangi, M; Vahed Jabbari, M (2009)Objective: Obese individuals are at high risk for developing endocrine and metabolic dysfunctions. Recent studies have linked obesity with alterations in the vitamin D endocrine system. Hypovitaminosis D can lead to ...
Dahifar, H; Faraji, A; Yassobi, S; Ghorbani, A (2007)Objective. Inadequate sunlight exposure and calcium intake during rapid growth at puberty lead to hypocalcemia, hypovitaminosis D and eventually to overt rickets. To determine serum biochemical findings of rickets in healthy ...
Clinical practices and therapeutic management of mineral and bone disorders in chronic kidney disease 4, 5 and 5D: The OCEANOS study in Iran Nafar, M; Farokhi, FR; Zeraati, AA; Ossareh, S; Atapour, A; Nemati, E; Gholi, FPR; Sagheb, MM; Hakemi, MS; Argani, H; Tara, SA; Afshar, R; Ahmadi, JMR; Karimi, N; Mamdouhi, F; Mahdavi-Mazdeh, M; Sabaghian, T (2018)Background: The aim of this study was to evaluate the management of mineral and bone disorders (MBD) in patients with chronic kidney disease (CKD) in Iran and the extent to which KDIGO goals were met. Methods: This ...